Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Systemic sclerosis: hypothesis-driven treatment strategies.

Christina Charles¹, Philip Clements, Daniel E Furst

¹Department of Medicine, Division of Rheumatology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-1670, USA.

Lancet (London, England)

|May 23, 2006

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Development of a single‑item patient‑reported measure of treatment side‑effect burden in clinical trials of rheumatic and musculoskeletal diseases using stakeholder input and large language model refinement.

Seminars in arthritis and rheumatism·2026

Same author

Measuring disease activity in juvenile systemic sclerosis: a multidisciplinary consensus from the Hamburg 2024 symposium.

Expert review of clinical immunology·2026

Same author

Integrated transcriptomic and epigenomic profiling reveals conserved molecular subtypes across systemic autoimmune diseases.

Annals of the rheumatic diseases·2026

Same author

Integrated single-cell transcriptomic analysis identifies <i>PF4</i> <sup><i>+</i></sup> <i>/PPBP</i> <sup><i>+</i></sup> megakaryocyte-like granulocytes associated with immune dysregulation in autoimmune diseases.

Biochemistry and biophysics reports·2026

Same author

Serum KL-6 and lung ultrasound B-lines: a combined non-invasive model for screening and predicting interstitial lung disease in idiopathic inflammatory myopathy.

RMD open·2026

Same author

Validity and utility of a single-item patient-reported measure of treatment-related bother in rheumatoid arthritis: A cross-sectional OMERACT study.

Seminars in arthritis and rheumatism·2026

Treatments targeting vascular complications in systemic sclerosis show success, improving quality of life and survival. While anti-fibrosis strategies are still developing, new approaches offer future promise for this complex autoimmune disease.

Area of Science:

Rheumatology
Immunology
Vascular Medicine

Background:

Systemic sclerosis is a complex autoimmune disease characterized by vascular damage, fibrosis, and immune system abnormalities.
Understanding the pathogenesis of systemic sclerosis is crucial for developing effective therapeutic strategies.

Purpose of the Study:

To review controlled and randomized controlled trials examining the pathogenesis of systemic sclerosis.
To evaluate the efficacy of current and emerging treatments for systemic sclerosis.

Main Methods:

Systematic review of data from controlled trials and randomized controlled trials.
Analysis of treatment strategies for vascular complications, fibrosis, and systemic features.

Main Results:

Related Experiment Videos

Therapies targeting vascular complications, such as renal crisis and pulmonary arterial hypertension, have demonstrated significant success.
Immunosuppressive therapy, particularly cyclophosphamide, shows efficacy, with autologous stem-cell transplantation trials ongoing.
Direct anti-fibrosis strategies (e.g., bosentan, interferon gamma, relaxin) have yielded disappointing results thus far.

Conclusions:

Vascular-targeted therapies are disease-modifying compounds for systemic sclerosis, improving patient function, quality of life, and survival.
New anti-fibrosis strategies based on molecular understanding hold promise for future systemic sclerosis treatments.
Simultaneous treatment of multiple disease features is a consideration for future clinical trials.